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Introduction
Prostate cancer diagnostics have recently evolved in terms of method (imaging and cognitive vs in-bore vs fusion-guided biopsies), route (transrectal vs transperineal), and sampling extent (targeted only vs systematic vs combination of targeted and systematic). Transrectal, transperineal, and in-bore MRIsupported biopsies were found to yield prostate cancer detection rates superior to conventional TRUS-guided 12 core biopsies [1] [2] [3] [4] [5] . Currently, there is conflicting evidence in studies comparing image-fusion and cognitive targeting [6] [7] [8] [9] [10] . For the sampling extent of biopsies, high probability MRI lesions were found to still require a combination of targeted MRI/US image-fusion and systematic transperineal biopsies [3, 11, 12] . Moreover, MRI may still miss Gleason score 7 cancer in 8-24% of patients on a lesion-by-lesion basis when prostatectomy serves as the reference standard [11, 13, 14] . The use of MRI in the setting of biopsy-na€ ıve men is thus currently not recommended in international guidelines [15, 16] . The PROstate MRI Imaging Study (PROMIS) study found that MRI outperforms conventional TRUS biopsy in biopsy-na€ ıve patients and suggests that MRI, if used as a triage test, could identify one quarter of men who might safely avoid unnecessary biopsy, without impairing the detection of clinically significant cancer [4] . Thus, the aim of the present study was to analyse the outcome of MRI-guided transperineal prostate biopsy, as first biopsy, in patients with a suspicion of prostate cancer in three different tertiary referral centres, either by MRI/US-fusion or cognitive targeting.
Patients and Methods

Standards of Reporting
The Standards of Reporting for MRI-targeted Biopsy Studies (START) were used to describe the study population, the conduct and reporting of the MRI, the conduct of the biopsy, and the results [17] . The biopsy technique and data collection were standardised according to the Ginsburg consensus [18] .
Study Population
All patients with first suspicion of prostate cancer without previous negative biopsies or previous diagnosis or treatment of prostate cancer were included in the evaluation. Patients aged >79 years (eight) and with a PSA level >30 ng/mL (41) were excluded from analysis to allow interpretation of results more relevant to a screening-based population, independent of a specific health system. The final study cohort comprised 807 patients all of whom underwent multiparametric MRI (mpMRI) and subsequent MRI supported transperineal prostate biopsies from 10/2012 to 05/2016: 163 at Centre I (Addenbrooke's Hospital, Cambridge, UK), 402 at Centre II (University Hospital Heidelberg, Heidelberg, Germany), and 242 at Centre III (Monash University, Melbourne, Australia). Indications for MRI and biopsy were raised PSA levels above age-related normal range (349 patients), a suspicious DRE (51), both (350), or other including family history (57). The patients' clinical characteristics are shown in Table 1 . Parts of the study populations in all centres were included in several publications addressing other aspects of transperineal prostate biopsies or prostate MRI interpretation [2, 11, 12, 19] .
Ethical Approval
All patients were counselled about the risks of the procedure and thereafter signed a consent form that included a permission to use their clinical data for research. The study was approved as a service evaluation by the local ethics committees at all centres.
MRI Analysis
The different MRI protocols are shown in Table S1 . All radiologists used team-based peer-review of images in equivocal cases and have ongoing histological feedback on >150 MRI/year. Feedback to radiologists was provided by quality management techniques, including complete prospective data collection, continuous data analysis and interpretation, and 3-6 monthly team meetings to action results, as well as weekly to monthly cancer multidisciplinary team meetings. Images were analysed according to the Prostate Imaging-Reporting and Data System (PI-RADS) version 1 [20] , and from 2015 on the subsequent PI-RADS version 2 [21] . The final overall PI-RADS score of each MRI was used for further analysis. If more than one target was present, the 'index lesion' with the highest PI-RADS score was used.
Biopsy
The Biopsee TM MRI/TRUS-fusion biopsy system (Medcom, Darmstadt, Germany) with a 5-mm spacing brachytherapy grid was used for MRI/US fusion and core placement planning in all biopsies in Centre I and II. In Centre III, all biopsies were performed cognitively using with a 5-mm spacing brachytherapy grid using a BK Medical (BK Ultrasound, Peabody, MA, USA) FlexFocus TM ultrasound with 8 848 transrectal probe mounted on a Civco (Kalona, IA, USA) MicroTouch TM stepper. All patients underwent systematic transperineal biopsies according to the Ginsburg protocol. A full description of the biopsy technique is available elsewhere [18, 19] . In brief, three to four biopsy cores were sampled from each of six sectors of the prostate. In patients with PI-RADS 3-5 MRI lesions, at least two biopsy cores were taken from each lesion before the systematic biopsies. To decrease the risk of sampling error caused by subsequent movement artefacts, bleeding and oedema, the lesion with the highest suspicion of cancer was targeted first. Specimens from each sector and targets were sent in separate specimen containers. In all, 395 patients underwent fusiontargeted transperineal biopsies in Centres I and II, 176 received cognitive targeting in Centre III. All procedures were done by one of three urologists with several years' experience of transperineal biopsy in Centre I, by supervised residents in Urology in Centre II, and one of five urologists in Centre III.
Histopathology
For the period of this study, all biopsies were graded with a Gleason score according to the International Society of Urological Pathology (ISUP) 2005 recommendations by at least one specialist uropathologist [22] .
Statistics
All data were collected prospectively in each centre. Descriptive statistics were used and positive (PPVs) and negative (NPVs) predictive values were calculated for the different PI-RADS groups, using the combined systematic transperineal biopsy and targeted biopsies as reference test, which has been recently validated by correlation with prostatectomy specimens [11] . In addition, PVs and detection rates were calculated for benign vs suspicious DRE, PSA levels of <4, 4-10, >10 ng/mL, as well as PSA densities (PSADs) of <0.1, 0.1-0.2 and >0.2 ng/mL/mL and combined for PSADs <0.1 and ≥0.1 ng/ml/mL, and for PSAD ≤0.15 and >0.15 ng/ml/mL, using the final overall histopathology results of the biopsy as validation, similar to a previously published study in patients after previous negative biopsy [23] . Detection rates of targeted cores and total combined biopsy were compared on a patient-perpatient basis for 507 cases with PI-RADS 3-5 lesions. Due to process errors, specimens from target biopsies and systematic sector were sent to histopathological analysis in the same container in 64 cases in Centre III and therefore excluded from this subgroup-analysis. Exact Fisher's and McNemar tests were used to test for statistical significance. Receiver-operating characteristic (ROC) curves and their respective area under the curve (AUC) were calculated for PSA level, PSAD, PI-RADS, and the combination of PSAD and PI-RADS. All statistical procedures were performed to a 5% significance level and are of explorative nature. The data were analysed using the Statistical Package for the Social Sciences (SPSS â , version 23; SPSS Inc., IBM Corp., Armonk, NY, USA).
Results
The patients' clinical characteristics and MRI findings are shown in Table 1 . One or more lesions suspicious for cancer on MRI (Likert scale 3-5) were found in 71% of the patients.
Prostate Cancer Detection, NPV and PPV
In all patients, cancer was detected in 546/807 (68%) and Gleason score 7-10 cancer in 392/807 (49%) (Fig. 1 , Table S2 ). The respective PVs for the different PI-RADS groups are shown in Table 2 and Table S3 . In the 236 patients without suspicious lesions, systematic biopsies detected cancer in 94 patients (40%), of whom 46 had Gleason score 3 + 3, 37 Gleason score 3 + 4, and 11 Gleason score ≥4 + 3. The resulting NPV of PI-RADS 1-2 was 0.80 (95% CI AE 0.05) for excluding Gleason score 7-10. Overall N = 807 Centre I n = 163 Centre II n = 402 Centre III n = 242 The PPV for Gleason score 7-10 cancer significantly increased with rising PSA levels for PI-RADS 4-5: from 0.55 (30/55) with a PSA level of <4 ng/mL to 0.69 (194/280) with a PSA level of 4-10 ng/mL to 0.87 (73/83) with a PSA level of >10 ng/mL (P < 0.001-0.042, Fig. 2b ). There was no significant difference for PI-RADS 1-3.
PSAD strongly influenced the detection rate of cancer and Gleason score 7-10 cancer (Table 3 , Fig. 2c ): the NPV for Gleason score 7-10 of PI-RADS 1-2 MRI was 0.91 (59/65) with a PSAD of <0.1 ng/mL/mL, 0.79 (98/124) with a PSAD of ≥0.1-0.2 ng/mL/mL, and 0.66 (31/47) with a PSAD of >0.2 ng/mL/mL (P = 0.011 with a threshold of 0.1 ng/mL/mL). For PI-RADS 3, the PPV for Gleason score 7-10 was 0.18 (7/39) with a PSAD of <0.1 ng/mL/mL, 0.31 (28/89) with a PSAD of ≥0.1-0.2 ng/mL/mL, and 0.48 (12/25) with a PSAD of >0.2 ng/mL/mL (P = 0.047 with a threshold of 0.1 ng/mL/mL). For PI-RADS 4-5, the PPV was 0.48 (35/73) with a PSAD of <0.1 ng/mL/mL, 0.66 (114/174) with a PSAD of ≥0.1-0.2 ng/mL/mL, and 0.87 (148/171) with a PSAD of >0.2 ng/mL/mL (P < 0.001 with a threshold of 0.1 ng/mL/mL). The respective AUCs are shown in Fig. 3 . Using a PSAD threshold of 0.15 ng/mL/mL, the NPV for Gleason score 7-10 of PI-RADS 1-2 MRI was 0.84 (121/144) with a PSAD of ≤0.15 ng/mL/mL and 0.73 (67/92) with a PSAD of >0.15 ng/ mL/mL (P = 0.047). For PI-RADS 3, the PPV for Gleason score 7-10 was 0.26 (26/100) with a PSAD of ≤0.15 ng/mL/mL and 0.40 (21/53) with a PSAD of >0.15 ng/mL/mL (P = 0.098). For PI-RADS 4-5, the PPV was 0.52 (85/162) with a PSAD of ≤0.15 ng/mL/mL and 0.83 (212/256) with a PSAD of >0.15 ng/mL/mL (P < 0.001).
Comparison of Targeted Cores, Systematic Cores and Total Biopsy
The combination of targeted and systematic biopsies was significantly better than either method alone for the detection of Gleason score 7-10 cancer in patients with suspicious lesions (PIRADS 4-5; Table 4 ). Systematic biopsies would not have detected 13 Gleason score 3 + 4 and 24 Gleason score ≥4 + 3 cancers (P < 0.001), whilst performing only targeted biopsies of suspicious lesions would have failed to diagnose 15 Gleason score 3 + 4 and 29 Gleason score ≥4 + 3 cancers (P < 0.001).
In equivocal lesions (PI-RADS 3), targeted biopsy alone would not have diagnosed six Gleason score 3 + 4 and six Gleason score ≥4 + 3 cancers, whereas performing only systematic biopsies would have only missed four Gleason score 3 + 4 and no Gleason score ≥4 + 3 cancers, with no significant difference in detection rate between either method alone and the combined biopsy (P > 0.05).
Centres II and III, which took four target cores per target, had significantly higher detection rates of Gleason score 7-10 cancer in their target cores than Centre I, which took only two target cores (P < 0.001-0.007), but did not show a corresponding increase in systematic detection rate. There was no significant difference in detection of any cancer between Centres I and II (P > 0.05).
Discussion
Our present study shows that in a first-biopsy setting, a negative MRI (PI-RADS 1-2) is associated with a NPV of 80% to detect Gleason score ≥7 prostate cancer as compared to a stringent reference test. In combination with a PSAD of ≤0.15 ng/mL/mL (18% of the study population) the NPV increased to 0.84, and with a PSAD of <0.1 ng/mL/mL (8% of the study population) the NPV increased to 0.91. The PSAD also strongly influenced the PPVs for equivocal and suspicious MRI (PI-RADS 3-5), with PPVs of up to 96% for any cancer and 87% for Gleason score 7-10 cancer with a PI-RADS 4-5 MRI and a PSAD of >0.2 ng/mL/mL. In patients with high probability MRI lesions, the significantly higher detection rates of Gleason score 7-10 cancer still required combined targeted and systematic MRI/TRUS image-fusion; however, systematic biopsy alone may be sufficient in patients with equivocal lesions with no significant difference to the combined approach.
Although our present data cannot provide a direct comparison of the transperineal Ginsburg scheme and 12-core TRUS biopsy, the detection rates with the Ginsburg scheme used in our multicentre analysis are similar to the results published for the extensive template-mapping biopsy with biopsy cores taken every 5 mm in the PROMIS trial and the PROMIS trial did find a clear advantage over 12-core TRUS biopsy [4] . This suggests that the MRI-guided Ginsburg biopsy scheme can provide similar histopathological validation yet using fewer cores than template biopsy and probably better diagnostic security than conventional 12-core TRUS biopsy. Regarding the sampling extent, the question remains whether systematic transperineal biopsy alone instead of a combined targeted and systematic approach could be sufficient enough for diagnostic evaluation of biopsy naive patients with suspicious MRI. The combined approach in our present study led to significantly higher detection rates of 71% of Gleason score 7-10 cancer for PI-RADS 4-5 lesions compared to 59% in the targeted and 61% in the systematic biopsy alone (P < 0.001). This corresponds to 71% of significant cancer identified by prostate templatemapping biopsy in patients with suspicious MRI findings in the recent PROMIS trial [4] . For equivocal MRI, we found 30% Gleason score 7-10 using the combined approach (21% with targeted, P < 0.001, and 27% with systematic-only biopsies, P > 0.05) compared to 21% by template mapping in the PROMIS study. In our present study, we found significantly higher detection rates of any cancer using the combined biopsy Of note, we found lower Gleason score 7-10 targeted-biopsy detection rates in Centre I, which took only two fusion-target cores, than Centre II with a median of four fusion-target cores, and highest in Centre III with four cognitive-target cores. This could indicate an advantage of higher target core numbers, with a denser sampling of target tissue, minimising any targeting error. Based on these data we advise to increase the number of cores taken in the target, aiming for saturation biopsy of the target region. MRI has been shown to significantly underestimate the final histopathological tumour volume at prostatectomy [24] [25] [26] [27] , providing a further rationale for this approach. More studies are needed to confirm which biopsy approach is better for increased detection of significant cancer and reduced detection of insignificant cancer.
In our present study, in a first-biopsy setting, both the NPV to detect Gleason score ≥7 prostate cancer in MRI-negative (PI-RADS 1-2) patients and the PPVs for equivocal and suspicious MRI (PI-RADS 3-5) patients for any cancer and for Gleason score 7-10 were improved when combined with PSAD stratification. Improved risk stratification with PSAD is consistent with the results of previous studies [23, 28] . Our present findings suggest that men with a PSAD of <0.1 ng/ mL/mL and a negative mpMRI may be spared a prostate biopsy (at least 8% of our present population). Whether a 9% risk of missing Gleason score ≥7 cancer (4% risk of Gleason ≥4 + 3) is acceptable is debatable, and the decision should be individualised. For equivocal MRI lesions, even in the group with a low PSAD of <0.1 ng/mL/mL, 18% of Gleason score 7-10 cancers would have been missed if these patients had not undergone biopsy. This is in contrast to the findings of Venderink et al. [5] who found only 6% significant cancer in patients with a PSAD of 0.15 ng/mL/mL and a PI-RADS 3 MRI by targeted in-bore biopsy, we therefore continue to advise our patients to undergo biopsy in cases of an equivocal MRI. Demographic factors such as DRE, PSA level or PSAD alone without the addition of MRI, were insufficient for predicting clinically significant cancer.
An NPV of 80% for Gleason score 7-10 in men with a negative MRI is lower than previous cohorts incorporating smaller patient numbers, with a NPV of >90% [29, 30] ; however, these used only 12-core systematic TRUS biopsies as validation, which is known to be an unreliable reference test [4] . Patients with previous TRUS biopsy are less likely to harbour significant disease [31] and biopsy-na€ ıve men therefore may need to be more closely followed if biopsy is omitted based on a negative MRI. Additionally, the background prevalence of cancer in our present cohort (overall 68%) was relatively high, which will impact on the NPV rate independent of the MRI as the reference test; a recently published meta-analysis reports an expected NPV of 47-79% with an overall cancer prevalence of 60-70% [32] . Likewise, our 80% NPV with 49% Gleason score 7-10 prevalence is comparable to the PROMIS study, where a NPV for a negative MRI ranged from 76% to 89% for significant cancer, with a Gleason score 7-10 cancer prevalence of 38% [4] , using a template-mapping biopsy as the 'gold standard' in biopsy-na€ ıve patients.
Our present study has the advantage of being prospective, with multicentre data collection according to an agreed template. The cohort is the largest reported involving purely biopsy-naive patients and is the only one offering information on combined NPV for negative MRI and PSAD in this common clinical scenario, providing evidence for the use of MRI-based biopsies. As not all patients underwent prostatectomy, we cannot provide the final 'gold standard' pathology for all cases in the study population. Nevertheless, our biopsy approach has recently been validated by correlation with prostatectomy specimens [11] . Limitations of the present study include the lack of data on comparability of individual radiological performance, urological operator experience, and histopathological Gleason grading amongst the different centres. The demographics of each centre, as well as the natural prevalence of prostate cancer in the different health communities, varied significantly: in Centre III, prostate volume (mean) was smaller and detection rates in the target cores, the systematic cores, and the total biopsy were higher than in the other centres. With a consequently increased PSAD, radiologists are more likely to see lesions with a higher grade; therefore they could perform better in MRI outcomes and, in the biopsy, more dense sampling in a smaller volume of prostate would make targeting per proportion of tissue more likely to be successful. Although data from each centre are available, we decided not to present centre comparative data or comparative data of fusion and cognitive targeting as it would not be statistically sound to Lastly, it has to be pointed out that our present results were obtained at high-volume, tertiary care centres with significant experience of prostate mpMRI and image-guided targeted biopsies. Translation of these results should therefore be made with caution [33] . The practice of using MRI for prostate biopsies truly requires a learning curve of the whole team in collaboration using quality management based on outcome data [34] .
Conclusions
MRI-supported transperineal prostate biopsy yielded high detection rates of Gleason score 7-10 cancer. Prostate biopsies may not be needed for men with low PSADs and unsuspicious MRIs. In patients with high probability lesions, denser sampling of target tissue may lead to increased detection rates in patients with suspicious MRI, and combined targeted and systematic MRI/TRUS image-fusion biopsies are recommended. 
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